Gene-Guided chemo trial aims to improve survival in tough breast cancer

NCT ID NCT05693766

Recruiting now Disease control Sponsor: Sonya Reid Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether using gene tests (MammoPrint and BluePrint) to guide treatment can help people with a certain type of advanced breast cancer (HR+, HER2-negative) live longer. 64 participants will receive either chemotherapy (capecitabine) or hormone therapy based on their gene signature. The study focuses on a diverse group to make findings more widely applicable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Capecitabine (chemotherapy) and endocrine therapy
What this could lead to: If successful, this could show that using gene tests to pick treatments improves survival for people with a hard-to-treat type of breast cancer.
What could go wrong: This is a small, early-phase trial (64 people) with no control group, so results may not apply broadly. Chemotherapy has side effects like fatigue and nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm hormone receptor-positive breast cancer invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE MAMMARY CARCINOMA METASTATIC BREAST CANCER

Contacts and locations

Locations

UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Alabama Birmingham
RECRUITING

Birmingham, Alabama, 35249, United States
Vanderbilt University/Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.